Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor

Independently developed by Sichuan Yingrui Pharmaceutical Technology Co., Ltd., CNSI-Fe is an innovative anti-cancer drug with Fe2+ as the active ingredient, which exerts anti-tumor effects by regulating the ferroptosis pathway. CNSI-Fe intratumoral injection has the following three effects: 1. Nanocarbon can increase the content of hydrogen peroxide in tumor cells and tumor microenvironment, and is a reactive oxygen species that catalyzes hydrogen peroxide through the Fenton reaction of iron ions to produce "ferroptosis", which complements each other; 2. The adsorption of Fe2+ by nanocarbon c

Trial Details

NCT ID
NCT07433283
Phase
PHASE1 / PHASE2
Sponsor
Sichuan Enray Pharmaceutical Sciences Company
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Carbon Nanoparticle-Loaded Iron [CNSI-Fe]
  • Carbon Nanoparticle-Loaded Iron
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Hunan, Changsha, China|32.92741,120.18021
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Haikou, Hainan, China|20.03421,110.34651

Key Eligibility Criteria

  • Patients must meet all of the following criteria to be eligible:
  • Understand and voluntarily sign the written informed consent form (ICF), be willing and able to comply with all trial requirements;
  • Male or female aged 18\~80 years old (including cut-off value) at the time of signing the ICF;
  • Stage Ib: patients with advanced solid tumors confirmed by histology or cytology, and the current standard therapy is ineffective (disease progress…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →